### UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

### WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED

Petitioner

v.

# NOVARTIS PHARMACEUTICALS CORPORATION

Patent Owner

Case IPR2018-\_\_\_\_

U.S. Patent No. 8,410,131

PETITIONER'S MOTION FOR JOINDER PURSUANT TO 35 U.S.C. § 315(c) AND 37 C.F.R. §§ 42.22 AND 42.122(b)

DOCKET

## **TABLE OF CONTENTS**

Table of Authoritiesii				
I.	Statement of Relief Requested1			
II.	Statement of Material Facts2			
III.	Argument			.3
	A.	Legal	Standards	.3
	B.	Joinder Is Appropriate		.4
		i.	No New Grounds of Unpatentability in the Petition	.6
		ii.	Joinder Will Not Impact the Board's Ability to Complete the Review in a Timely Manner	.7
		iii.	Briefing and Discovery Will Be Simplified	.9
		iv.	No Prejudice to Patent Owner	10
IV.	Conc	lusion		10

### **TABLE OF AUTHORITIES**

### Cases

<i>Dell Inc. v. Network-1 Sec. Solutions, Inc.,</i> IPR2013-00385, Paper No. 17 (July 29, 2013)				
Enzymotec Ltd. v. Neptune Techs & Bioresources, Inc., IPR2014-00556, Paper No. 19 (July 9, 2014)4				
<i>MediaTek Inc., et al. v. Bandspeed, Inc.,</i> IPR2015-00314, Paper No. 20 (Sept. 17, 2015)6				
SAP America Inc. v. Clouding IP, LLC, IPR2014-00306, Paper No. 13 (May 19, 2014)				
Statutes				
35 U.S.C. § 315(b)				
35 U.S.C. § 315(c)				
35 U.S.C. § 316(a)(11)7, 9				
35 U.S.C. § 317(a)				
Rules				
37 C.F.R. § 42.22				
37 C.F.R. § 42.100(c)				
37 C.F.R. § 42.101(b)				
37 C.F.R. § 42.122				
37 C.F.R. § 42.122(b)				
Other Authorities				
157 CONG. REC. S1376 (daily ed. Mar. 8, 2011)				

### I. STATEMENT OF RELIEF REQUESTED

West-Ward Pharmaceuticals International Limited ("West-Ward" or "Petitioner") respectfully submits this Motion for Joinder, together with a Petition for Inter Partes Review ("the West-Ward Petition") of claims 1-3 and 5-9 of U.S. Patent No. 8,410,131 ("the '131 patent"). Pursuant to 35 U.S.C. § 315(c) and 37 C.F.R. § 42.122(b), Petitioner requests inter partes review and joinder with Breckenridge Pharmaceutical, Inc. v. Novartis Pharmaceuticals Corporation, IPR2017-01592 (the "Breckenridge IPR"), which was instituted on January 3, 2018. Joinder is appropriate because it will promote efficient and consistent resolution of the unpatentability grounds at issue and will not prejudice any of the parties to the Breckenridge IPR. Petitioner has requested consent from Breckenridge Pharmaceutical, Inc. ("Breckenridge") to file this motion for joinder. To date, Breckenridge has not indicated its position regarding Petitioner's request. Absent joinder, West-Ward will be prejudiced because its interests may not be adequately represented in the Breckenridge IPR.

This Motion for Joinder and accompanying Petition are being filed within one month of the decision instituting trial in the Breckenridge IPR, and are therefore timely. 37 C.F.R. §§ 42.22, 42.122(b).

**R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

### II. STATEMENT OF MATERIAL FACTS

 Novartis Pharmaceuticals Corporation ("Novartis" or "Patent Owner") owns the '131 patent. Novartis sued West-Ward (previously Roxane Laboratories, Inc.), in the United States District Court for the District of Delaware, for infringement of the '131 patent in 2015 and final judgment was entered in favor of Novartis in December 2017.

2. On June 12, 2017, Breckenridge filed a petition for *inter partes* review of claims 1-3 and 5-9 of the '131 patent. *See* IPR2017-01592, Paper No. 1.

**3.** On January 3, 2018, the Board instituted an *inter partes* review of claims 1-3 and 5-9 of the '131 patent. *See* IPR2017-01592, Paper No. 12.

4. West-Ward's Petition that accompanies the present Motion for Joinder is filed within one month of the January 3, 2018 decision to institute the Breckenridge IPR, and includes only the same grounds of unpatentability that were instituted in the Breckenridge IPR. West-Ward's Petition is timely under 37 C.F.R. § 42.122, which provides that the time period set forth in 37 C.F.R. § 42.101(b) shall not apply when the petition is accompanied by a request for joinder.

2

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.